Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | CCR3 | P51677 | 4/20 | 0.45 |
| ▸ | CCR1 | P32246 | 3/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ATP4A | P20648 | 2/20 | 0.38 |
| ▸ | ATP4B | P51164 | 2/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214628 | 0.88 | SIGMAR1 (0.58) | SIGMAR1CCR3CCR1MCHR1MEN1 | |
| SCHEMBL2212418 | 0.86 | SIGMAR1 (0.46) | SIGMAR1CCR3CCR1MCHR1MEN1 | |
| SCHEMBL2210839 | 0.84 | MCHR1 (0.51) | SIGMAR1CCR3CCR1MCHR1MEN1 | |
| SCHEMBL2212720 | 0.83 | SIGMAR1 (0.47) | SIGMAR1CCR3CCR1MCHR1MEN1 | |
| SCHEMBL2213939 | 0.82 | UTS2R (0.48) | SIGMAR1CCR3CCR1MCHR1MEN1 | |
| SCHEMBL6106152 | 0.80 | CCR3 (0.61) | SIGMAR1CCR3CCR1MCHR1MEN1 | |
| SCHEMBL2211685 | 0.77 | SIGMAR1 (0.57) | SIGMAR1CCR3CCR1MCHR1MEN1 | |
| SCHEMBL2210703 | 0.76 | CCR3 (0.61) | SIGMAR1CCR3CCR1MCHR1MEN1 | |
| SCHEMBL12511823 | 0.74 | CCR3 (0.53) | SIGMAR1CCR3CCR1MCHR1MEN1 | |
| SCHEMBL4036167 | 0.73 | SIGMAR1 (0.70) | SIGMAR1CCR3CCR1MCHR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7115635-B2 | Benzylpiperidine compound | MITSUBISHI PHARMA CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1389616-A1 | NOVEL BENZYLPIPERIDINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | SIGMAR1 2000/4885CCR3 21/4885CCR1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.